
2026-04-09
Chithandizo cha khansa ya m'mapapo pofika chaka cha 2026 chimatanthawuza njira zokhazikika, zozikidwa ndi umboni zomwe zimagwiritsidwa ntchito ku China kuthana ndi khansa ya m'mapapo yoyambirira kutengera kufalikira kwake. Zaposachedwa 2026 Malangizo a Chithandizo cha China tsindikani zakusintha kwamankhwala olondola, kuphatikiza machiritso omwe amayang'aniridwa ndi maselo ndi chitetezo chamthupi limodzi ndi mankhwala achikhalidwe komanso ma radiation. Kwa matenda oyambilira, opaleshoni imakhalabe yochiritsira, pomwe kasamalidwe ka Stage IV tsopano akuyika patsogolo mbiri ya chibadwa kuti asankhe njira zabwino zochiritsira, kukulitsa kwambiri moyo ndikusintha moyo wa odwala mamiliyoni ambiri.
Masitepe olondola ndiye mwala wapangodya wogwira ntchito Chithandizo cha khansa ya m'mapapo ndi siteji. Mu 2026, akatswiri a oncologists aku China amatsatira mosamalitsa 9th Edition ya TNM staging system yokhazikitsidwa ndi International Association for the Study of Lung Cancer (IASLC). Dongosololi limayika zotupa kutengera kukula (T), kukhudzidwa kwa ma lymph node (N), ndi metastasis yakutali (M). Kumvetsetsa magawowa ndikofunikira chifukwa njira zochiritsira zimasiyana kwambiri pakati pa kukula komwe kumapezeka komanso matenda ofala.
Maonekedwe a khansa ya m'mapapo ku China akadali ovuta. Deta yochokera ku National Cancer Center ikuwonetsa kuti khansa ya m'mapapo ndiyo chotupa choopsa kwambiri, chomwe chili ndi matenda atsopano pafupifupi 1.06 miliyoni ndi imfa 733,300 zomwe zinalembedwa mu 2022. Ngakhale kuti anthu ambiri akudziwitsa anthu za kuyezetsa, gawo lalikulu la odwala amapezeka pa Stage IV. Chifukwa chake, a 2026 malangizo ikani chidwi kwambiri pakukhathamiritsa zotsatira za matenda apamwamba pomwe mukulimbitsa ma protocol ozindikira msanga.
Tanthauzo la chisamaliro chokhazikika chasintha. Ngakhale chemotherapy inali msana wokhawo wamankhwala, zosintha za 2026 zimazindikira izi mankhwala olimbana ndi maselo ndi immunotherapy tsopano ndi mizati yapakati. Zosankha zachipatala sizilinso zochokera ku histology (monga adenocarcinoma vs. squamous cell carcinoma) koma zimayendetsedwa ndi kusintha kwachibadwa. Kusintha kwa paradigm uku kumatsimikizira kuti odwala amalandira mankhwala othandiza kwambiri pa biology yawo yotupa.
Kwa odwala omwe ali ndi khansa ya Stage I ndi Gawo II yomwe si yaing'ono ya m'mapapo ya m'mapapo (NSCLC), cholinga chachikulu ndikuchiritsa. Maupangiri aku China a 2026 akutsimikiziranso kuti kuchotsedwa kwa maopaleshoni ndiye mulingo wagolide kwa omwe angathe kugwira ntchito. Komabe, njira yopangira opaleshoni ndi chithandizo cha adjuvant yakhala yovuta kwambiri kuti mukhale ndi moyo wautali.
Opaleshoni ikadali njira yothandiza kwambiri yochotsera zotupa zoyamba kumene. M'zipatala zazikulu zachipatala za ku China, Video-Assisted Thoracoscopic Surgery (VATS) ndi Robot-Assisted Thoracic Surgery zakhala zofala. Njira zochepetsera pang'ono izi zimachepetsa nthawi yochira komanso zovuta poyerekeza ndi thoracotomy yachikhalidwe yotseguka.
Chithandizo cha pambuyo pa opaleshoni, chomwe chimadziwika kuti adjuvant therapy, n'chofunika kwambiri pofuna kuthetsa matenda aang'ono komanso kupewa kuyambiranso. Maupangiri a 2026 amapereka malingaliro osinthidwa kutengera mayeso aposachedwa azachipatala.
Kwa odwala a Stage IB mpaka IIIA omwe ali ndi masinthidwe enieni a chibadwa, monga EGFR positivity, adjuvant targeted therapy tsopano ikulimbikitsidwa kwambiri. Izi zikuyimira kupita patsogolo kwakukulu kuposa zaka zam'mbuyomu pomwe chemotherapy inali njira yokhayo. Momwemonso, kwa odwala omwe alibe masinthidwe oyendetsa koma okhala ndi mawu apamwamba a PD-L1, adjuvant immunotherapy angagwiritsidwe ntchito potsatira chemotherapy-based chemotherapy.
Gawo lachitatu la khansa ya m'mapapo ndizovuta zomwe matendawa afalikira ku ma lymph nodes oyandikana nawo koma osati ku ziwalo zakutali. Gawoli nthawi zambiri limatchedwa "kupita patsogolo." Njira yochizira imafunikira gulu lamitundu yosiyanasiyana lomwe limaphatikizapo maopaleshoni, akatswiri azachipatala, ndi ma radiation oncologists.
Mwala wapangodya wa chithandizo cha Stage III ndi multimodal mankhwala, yomwe imaphatikiza njira zosiyanasiyana zochiritsira. Kutsatizana kwake kumadalira ngati chotupacho chimaonedwa kuti ndi chosiyana.
Kupambana pakuwongolera matenda osasinthika a Gawo III ndikugwiritsa ntchito consolidation immunotherapy. Pambuyo pomaliza mankhwala a chemoradiotherapy, odwala omwe sanapite patsogolo amathandizidwa ndi immune checkpoint inhibitors. Maupangiri a 2026 akuwunikira njira iyi ngati njira yofunika kwambiri yomwe yathandizira kwambiri kupulumuka kopanda kupita patsogolo komanso kupulumuka kwathunthu kwa anthu aku China.
Gawo IV, kapena khansa ya m'mapapo ya metastatic, imachitika pamene matendawa afalikira ku ziwalo zakutali monga ubongo, mafupa, chiwindi, kapena mapapo ena. M'mbiri, kuneneratu kwa Gawo IV kunali koyipa, ndi nthawi zamoyo zachilengedwe kuyambira 1 mpaka mwezi wa 3. Komabe, a 2026 Malangizo a Chithandizo cha China zikuwonetsa kusintha kwakukulu kwa zotsatira chifukwa cha kupita patsogolo kwa njira zochiritsira.
Musanayambe chithandizo cha Stage IV NSCLC, kuyezetsa kwathunthu kwa maselo ndikofunikira. Malangizowo akugogomezera kuti biopsy ya minofu kapena yamadzimadzi biopsy (kuyesa magazi) iyenera kuchitidwa kuti muwone kusintha kwa oyendetsa. Zolinga zodziwika bwino ndi monga EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, ndi NTRK.
Chifukwa chiyani kuyesa kuli kofunika: Kuzindikira kusintha kwina kumalola asing'anga kuti apereke mankhwala amkamwa omwe ali othandiza kwambiri komanso opanda poizoni kuposa mankhwala achikhalidwe. Kwa odwala omwe alibe kusintha kosinthika, kuyesa kwa PD-L1 kumawongolera kugwiritsa ntchito immunotherapy.
Kusintha kwa 2026 kumaphatikizapo mankhwala onse atsopano ovomerezedwa ndi National Medical Products Administration (NMPA) ya ku China mpaka kumapeto kwa 2025. Izi zikuphatikizapo EGFR inhibitors ya m'badwo wachitatu ndi ALK inhibitors a m'badwo wotsatira omwe ali ndi luso lapamwamba lolowera chotchinga cha ubongo wa magazi.
Kwa odwala omwe alibe masinthidwe oyendetsa, immunotherapy kuphatikiza ndi chemotherapy yakhala muyeso watsopano. Malangizowa amalimbikitsa machitidwe osiyanasiyana otengera histological subtype (squamous vs. non-squamous) ndi PD-L1 mawu ofotokozera. Pamafotokozedwe apamwamba a PD-L1, immunotherapy monotherapy itha kuganiziridwa kuti ipulumutse odwala ku chemotherapy poizoni.
Ma metastases muubongo ndizovuta komanso zovuta kwambiri za khansa ya m'mapapo, zomwe zimakhudza odwala ambiri a Gawo IV. Mu Januware 2026, China idatulutsa odzipereka "Malangizo aku China a Chithandizo cha Khansa Yam'mapapo Metastases ya Ubongo (2026 Edition)". Chikalatachi chikufotokoza zovuta zenizeni zochizira khansa yomwe yafalikira ku ubongo.
Malangizowa amafotokoza izi momveka bwino Magnetic Resonance Imaging (MRI) wa mutu ndiye njira yofananira yomwe imakonda yowunikira ndikuwunika ma metastases muubongo. Ma CT scans ndi osakwanira kuti azindikire zilonda zazing'ono. Kuwunika pafupipafupi kwa MRI kumalimbikitsidwa kwa odwala omwe ali pachiwopsezo chachikulu ngakhale palibe zizindikiro zaubongo.
Kasamalidwe ka metastases muubongo kumafuna njira yolumikizirana yophatikizira machiritso am'deralo ndi amthupi:
Ngakhale kuti Khansa Yam'mapapo Yosakhala Yang'ono Yang'ono (NSCLC) imakhala pafupifupi 85% ya milandu, Cancer ya Small Cell Lung Cancer (SCLC) ndi mtundu wosiyana komanso wankhanza. Maupangiri a 2026 amasunga njira yosiyanitsira ya SCLC chifukwa chakukula kwake mwachangu komanso kuyambika kwa metastasis.
SCLC ili m'gulu la Limited Stage (yokhala ndi hemithorax imodzi) ndi Extensive Stage (yofalikira kupitirira).
Kumvetsetsa zazachuma ndikofunikira kwa odwala omwe akufuna Chithandizo cha khansa ya m'mapapo ndi siteji ku China. Mtengo wake umasiyana kwambiri kutengera siteji, njira yamankhwala, gawo lachipatala, komanso inshuwaransi. Dongosolo la zaumoyo ku China lapita patsogolo kwambiri pakuchepetsa kulemedwa kwa odwala kudzera mu National Reimbursement Drug List (NRDL).
Mitengo nthawi zambiri imakhala yotsika ku China poyerekeza ndi mayiko akumadzulo, makamaka pamankhwala opangidwa ndi inshuwaransi yadziko lonse.
Dongosolo la Basic Medical Inshuwalansi ku China limapereka mankhwala ambiri othana ndi khansa. Maupangiri a 2026 amaganizira makamaka za kupezeka kwa mankhwala ndi momwe angabwezeredwe popanga malingaliro. Odwala amalangizidwa kuti afunsane ndi ogwira ntchito m'chipatala kapena akatswiri a inshuwaransi kuti awonjezere phindu lawo. Kuphatikiza apo, inshuwaransi yowonjezera yazamalonda ndi mapulogalamu othandizira othandizira amachepetsanso zovuta zachuma m'mabanja.
Kupeza chisamaliro chapamwamba ndikofunikira kuti pakhale zotsatira zabwino. China ili ndi malo angapo a khansa padziko lonse lapansi omwe amatsogolera pakufufuza komanso kugwiritsa ntchito malangizo azachipatala a 2026. Pofufuza zipatala pafupi ndi ine, odwala ayenera kuyang'ana mabungwe omwe ali ndi madipatimenti apadera a thoracic oncology.
Zipatala zina ku China zimadziwika mdziko lonse chifukwa cha ukadaulo wawo pakuwongolera khansa ya m'mapapo:
Posankha chipatala, ganizirani zotsatirazi:
Kuti mumvetsetse bwino zosankha zomwe zilipo pansi pa malangizo a 2026, tebulo lotsatirali likufanizira njira zoyambira zamankhwala zomwe zimagwiritsidwa ntchito ku China masiku ano.
| Makhalidwe | Makhalidwe Ofunikira | Njira Yabwino Yogwiritsira Ntchito |
|---|---|---|
| Opaleshoni | Cholinga chochizira, chosokoneza, chimafuna nthawi yochira | Gawo I, II, ndikusankha Stage III NSCLC |
| Chemotherapy | Systemic, cytotoxic, maziko koma poizoni | Magawo onse (adjuvant/neoadjuvant), SCLC, zosunga zobwezeretsera ena |
| Chithandizo Chachindunji | Mapiritsi amkamwa, olondola, otsika kawopsedwe, kukana kotheka | Stage IV NSCLC yokhala ndi masinthidwe apadera oyendetsa (EGFR, ALK, etc.) |
| Immunotherapy | Kulowetsedwa, imayendetsa chitetezo cha m'thupi, cholimba mayankho | Gawo III/IV NSCLC yopanda madalaivala, SCLC siteji yayikulu |
| Ma radiation (SRS/WBRT) | Kuwongolera kwanuko, kosasokoneza, mwachindunji ku ubongo/thupi | Matenda a metastases muubongo, omwe atsogola m'dera lanu matenda osasinthika |
Kuyendera dongosolo lazaumoyo kungakhale kovuta. Pansipa pali njira yowongoka ya wodwala yemwe akuganiziridwa kuti ali ndi khansa ya m'mapapo ku China, yogwirizana ndi malangizo aposachedwa.
Kukhazikitsidwa kwa malangizo a 2026 kumabweretsa phindu lalikulu komanso kumapereka zovuta zina zomwe odwala ndi opereka chithandizo ayenera kutsata.
Malangizo a 2026 amatsindika kwambiri kupewa komanso kuzindikira msanga. National Health Commission yapereka njira zenizeni zoyezera khansa ya m'mapapo, yoyang'ana anthu omwe ali pachiwopsezo chachikulu. Kuzindikira koyambirira kumakhalabe njira imodzi yothandiza kwambiri yosinthira moyo wazaka 5.
Kuwunika kumalimbikitsidwa kwa anthu azaka zapakati pa 50 mpaka 74 omwe amakwaniritsa chimodzi mwazinthu izi:
Low-Dose Spiral CT (LDCT) ndi njira yokhayo yovomerezeka yowunikira. Ma X-ray pachifuwa amakhumudwitsidwa mwatsatanetsatane chifukwa amaphonya timadontho tating'ono tating'ono. Maupangiri amafotokoza kuti LDCT iyenera kuchitidwa pogwiritsa ntchito makina ojambulira okhala ndi mizere yosachepera 16, yotanthauziridwa ndi akatswiri odziwa ma radiology.
Pamene tikupitilira mu 2026, gawo la chithandizo cha khansa ya m'mapapo likupitilira kukula mwachangu. Kafukufuku akuyang'ana kwambiri kuthana ndi kukana kwa mankhwala, kuphatikiza machiritso a synergistic zotsatira, ndikupanga katemera.
Antibody-drug conjugates (ADCs) akubwera ngati gulu latsopano lamphamvu lamankhwala, kuwonetsa kulonjeza kwa odwala omwe adalephera kuchiritsa komwe adawatsata m'mbuyomu. Kuphatikiza apo, luntha lochita kupanga likuphatikizidwa kwambiri mu radiology kuti azindikire tinthu tating'onoting'ono kale ndikulosera mayankho amankhwala molondola.
Kudzipereka kwa mabungwe azachipatala aku China kuti azisintha malangizo pafupipafupi kumawonetsetsa kuti odwala amapindula ndi zomwe zachitika posachedwa zasayansi mosazengereza. Mgwirizano wapakati pamakampani opanga mankhwala apanyumba ndi mabungwe ofufuza padziko lonse lapansi ukufulumizitsa kupezeka kwamankhwala amakono ku China.
Malo a Chithandizo cha khansa ya m'mapapo ndi siteji mu 2026 amatanthauzidwa ndi kulondola, makonda, ndi chiyembekezo. Kutulutsidwa kwa 2026 Malangizo a Chithandizo cha China ndi chizindikiro chofunika kwambiri, kuphatikiza zaka za kafukufuku wa njira zachipatala zomwe zingatheke. Kuchokera pakuchiritsa kwa opaleshoni koyambirira mpaka kukulitsa moyo wamankhwala omwe akuwunikiridwa ndi chitetezo chamthupi mu Gawo IV, odwala masiku ano ali ndi zosankha zambiri kuposa kale.
Ngakhale zovuta monga kuzindikirika msanga ndi kukana mankhwala zikupitilirabe, njira yokhazikika yomwe akatswiri otsogola aku China amawunikira imapereka njira yodalirika yosamalira. Pogwiritsa ntchito njira zowunikira zapamwamba, kutsatira malamulo okhazikika, komanso kugwiritsa ntchito chithandizo chokwanira chachipatala cha dziko lonse, kuneneratu kwa odwala khansa ya m'mapapo ku China kukupitilirabe. Kwa aliyense amene akukhudzidwa ndi matendawa, kumvetsetsa magawowa ndi chithandizo chomwe chilipo ndi sitepe yoyamba yoyendetsa ulendowu molimba mtima komanso kupeza chithandizo chabwino kwambiri.